Exubera Reimbursement Plan May Focus On Outcomes Relative To Oral Agents
Executive Summary
Pfizer's strategy for securing reimbursement for Exubera could focus on the inhaled insulin's benefits on overall healthcare outcomes relative to oral diabetes therapies